Nanoparticles for cellular drug delivery: Mechanisms and factors influencing delivery

被引:137
作者
Chavanpatil, Mahesh D.
Khdair, Ayman
Panyam, Jayanth [1 ]
机构
[1] Wayne State Univ, Dept Pharmaceut Sci, Eugene Applebaum Coll Pharm & Hlth Sci, Detroit, MI 48201 USA
[2] Wayne State Univ, Karmanos Canc Inst, Detroit, MI 48201 USA
关键词
gene delivery; endocytosis; receptors; ligands; antibodies; trafficking;
D O I
10.1166/jnn.2006.443
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Polymeric nanoparticles have demonstrated enormous potential as cellular drug delivery vehicles. Nanoparticles improve drug's stability as well as its availability and retention at the target intracellular site of action. Therapeutic efficacy of nanoparticles can be further enhanced by conjugating specific ligands to nanoparticle surface. Ligand conjugation can also be used to favorably modify the intracellular disposition of nanoparticles. A number of ligands are available for this purpose; use of a specific ligand depends on the target cell, the material used for nanoparticle formulation, and the chemistry available for ligand-nanoparticle conjugation. Cellular drug delivery using nanoparticles is also affected by clearance through the reticuloendothelial system. In this paper, we review the recent progress on our understanding of physicochemical factors that affect the cellular uptake of nanoparticles and the different cellular processes that could be exploited to enhance nanoparticle uptake into cells.
引用
收藏
页码:2651 / 2663
页数:13
相关论文
共 117 条
[11]   NA+-DEPENDENT BIOTIN TRANSPORT INTO BRUSH-BORDER MEMBRANE-VESICLES FROM HUMAN KIDNEY CORTEX [J].
BAUR, B ;
BAUMGARTNER, ER .
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 1993, 422 (05) :499-505
[12]  
Bejjani R, 2005, MOL VIS, V11, P124
[13]   Delivery of peptides and proteins through the blood-brain barrier (Reprinted from Advanced Drug Delivery Reviews, vol 10, pg 205-245, 1993) [J].
Bickel, U ;
Yoshikawa, T ;
Pardridge, WM .
ADVANCED DRUG DELIVERY REVIEWS, 2001, 46 (1-3) :247-279
[14]  
Blau S, 2000, CRIT REV THER DRUG, V17, P425
[15]   DRUG TARGETING - SYNTHESIS AND ENDOCYTOSIS OF OLIGONUCLEOTIDE-NEOGLYCOPROTEIN CONJUGATES [J].
BONFILS, E ;
DEPIERREUX, C ;
MIDOUX, P ;
THUONG, NT ;
MONSIGNY, M ;
ROCHE, AC .
NUCLEIC ACIDS RESEARCH, 1992, 20 (17) :4621-4629
[16]  
CATIZONE A, 1993, CELL MOL BIOL, V39, P155
[17]   Immunotargeting of glucose oxidase to endothelium in vivo causes oxidative vascular injury in the lungs [J].
Christofidou-Solomidou, M ;
Pietra, GG ;
Solomides, CC ;
Arguiris, E ;
Harshaw, D ;
Fitzgerald, GA ;
Albelda, SM ;
Muzykantov, VR .
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2000, 278 (04) :L794-L805
[18]   INHIBITION OF LEUKEMIA-CELL PROLIFERATION BY FOLIC-ACID POLYLYSINE-MEDIATED INTRODUCTION OF C-MYB ANTISENSE OLIGODEOXYNUCLEOTIDES INTO HL-60 CELLS [J].
CITRO, G ;
SZCZYLIK, C ;
GINOBBI, P ;
ZUPI, G ;
CALABRETTA, B .
BRITISH JOURNAL OF CANCER, 1994, 69 (03) :463-467
[19]   Development of tumor targeting bioprobes (111In-chimeric L6 monoclonal antibody nanoparticles) for alternating magnetic field cancer therapy [J].
DeNardo, SJ ;
DeNardo, GL ;
Miers, LA ;
Natarajan, A ;
Foreman, AR ;
Gruettner, C ;
Adamson, GN ;
Ivkov, R .
CLINICAL CANCER RESEARCH, 2005, 11 (19) :7087S-7092S
[20]   The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent [J].
Desai, MP ;
Labhasetwar, V ;
Walter, E ;
Levy, RJ ;
Amidon, GL .
PHARMACEUTICAL RESEARCH, 1997, 14 (11) :1568-1573